Related references
Note: Only part of the references are listed.Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? A Systematic Review
Aaron P. Mitchell et al.
ANNALS OF INTERNAL MEDICINE (2021)
Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019
Alexandra Erath et al.
JAMA NETWORK OPEN (2020)
Older Drugs With Limited Trial Evidence: Are They Worth the Expense? IN RESPONSE
Ali Duarte-Garcia et al.
ANNALS OF INTERNAL MEDICINE (2019)
National Health Care Spending In 2016: Spending And Enrollment Growth Slow After Initial Coverage Expansions
Micah Hartman et al.
HEALTH AFFAIRS (2018)
2015 American College of Rheumatology Workforce Study: Supply and Demand Projections of Adult Rheumatology Workforce, 2015-2030
Daniel F. Battafarano et al.
ARTHRITIS CARE & RESEARCH (2018)
Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing
Scott E. Hadland et al.
JAMA INTERNAL MEDICINE (2018)
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
William Fleischman et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
William Fleischman et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts
James S. Yeh et al.
JAMA INTERNAL MEDICINE (2016)
Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries
Colette DeJong et al.
JAMA INTERNAL MEDICINE (2016)
Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists
Stanford C. Taylor et al.
JAMA OPHTHALMOLOGY (2016)
Regulatory And Cost Barriers Are Likely To Limit Biosimilar Development And Expected Savings In The Near Future
Henry G. Grabowski et al.
HEALTH AFFAIRS (2014)
Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales
John P. A. Ioannidis et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Trends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare Program
Jie Zhang et al.
ARTHRITIS CARE & RESEARCH (2013)
Lack of Head-to-head Trials and Fair Control Arms Randomized Controlled Trials of Biologic Treatment for Rheumatoid Arthritis
Candice Estellat et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
The effect of incentive-based formularies on prescription-drug utilization and spending
HA Huskamp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Physicians and the pharmaceutical industry - Is a gift ever just a gift?
A Wazana
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
